Skip to main content

Early data show promise for the FGFR inhibitor rogaratinib

Pills in hand

The FGFR inhibitor rogaratinib is well tolerated and clinically active in patients with various tumor types selected for treatment on the basis of FGFR mRNA overexpression, phase I study data show.


Support for switching between upadacitinib and adalimumab in RA patients

Rheumatoid arthritis medication

48-week results from the SELECT-COMPARE study indicate that upadacitinib has sustained efficacy in patients with rheumatoid arthritis, and that individuals with an inadequate response to upadacitinib or adalimumab may benefit from switching to the alternate therapy.


Monocyte counts could predict IPF outcome


Elevated monocyte counts are associated with poor outcomes among patients with idiopathic pulmonary fibrosis, suggest study findings published in The Lancet Respiratory Medicine.

Headlines from across medwireNews

23-08-2019 | Oncology | News | Article

Entrectinib gains two indications in USA

Details of this FDA decision are a click away

23-08-2019 | Rheumatology | News | Article

US guidelines for the treatment of axSpA published

The ACR, Spondylitis Association of America, and Spondyloarthritis Research and Treatment Network have issued updated recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis.

23-08-2019 | Rheumatology | News | Article

Antibiotic exposure may influence the odds of developing RA

Exposure to systemic oral antibiotics is associated with a higher risk for rheumatoid arthritis, a database analysis suggests.

23-08-2019 | Diabetes | News | Article

CANVAS canagliflozin fracture effect may be chance finding

A comparison of CANVAS and CANVAS-R fails to detect any potential explanation for the increased fracture risk seen with canagliflozin versus placebo in the former trial.

22-08-2019 | Rheumatology | News | Article

Neutrophil biomarkers show promise for predicting RA prognosis

Neutrophil-derived biomarkers correlate with disease activity and can predict joint space narrowing and erosive disease among patients with rheumatoid arthritis, researchers report.

21-08-2019 | Diabetes | News | Article

Lack of omega-3 effect on type 2 diabetes confirmed

A systematic review and meta-analysis published in The BMJ confirms that intake of omega-3 fats does not influence the risk for or progression of type 2 diabetes.

medwireNews is an established provider of authoritative, timely and independent medical news. We value your feedback and encourage you to contact us to make your preferred medical news resource.

Meet the team

Image Credits